Serotonergic psychedelic treatment for obesity and eating disorders: potential expectations and caveats for emerging studies
Journal of Psychiatry and Neuroscience – June 01, 2022
Source: OpenAlex
Summary
A significant shift in Psychiatry is underway, as serotonergic psychedelics, including the classic hallucinogen Lysergic acid diethylamide, increasingly enter mainstream Medicine. Numerous clinical trials are exploring their potential for major depressive disorder, substance use disorder, and even eating disorders. This burgeoning field within Psychology and Psychedelics and Drug Studies highlights how these compounds, often from chemical synthesis and alkaloids, influence behavior through neurotransmitter receptor interaction, offering new therapeutic avenues.
Abstract
There has been a substantial growth in private clinics and registered clinical trials employing serotonergic psychedelics for various psychiatric illnesses, including substance use disorder[1][1],[2][2] and major depressive disorder.[3][3]–[6][4] Classical psychedelics include lysergic acid